Health technology assessment has long been a pivotal tool in guiding resource allocation by systematically evaluating the economic, clinical, and social impacts of health interventions. However, Siriram and Harris’s reflection highlights a crucial blind spot: while cost-effectiveness has dominated HTA, it frequently overlooks the layered disparities etched by social determinants, infrastructure limitations, and cultural contexts unique to LMICs. The commentary posits that to foster true health justice, HTA must transcend these economic boundaries and incorporate nuanced equity considerations.

South Africa stands as a focal example in their analysis, representing both the strides and struggles in implementing HTA frameworks that honor equity. The country’s diverse socioeconomic landscape and stark health disparities create a complex environment where uniform cost-effectiveness thresholds find little purchase. Siriram and Harris argue that without a shift toward equity-informed evaluations, new health technologies risk reinforcing, if not exacerbating, existing inequalities by benefit distribution skewed toward more privileged populations.

Central to the authors’ thesis is the proposition of adapting global HTA methodologies to be reflexive and locally responsive rather than prescriptive and generic. Traditional models, often born in high-income contexts, fail to resonate with the health challenges and priorities in LMIC settings. Instead, they propose embedding participatory approaches that incorporate voices from marginalized communities, health workers, and policymakers directly affected by these decisions. This inclusive engagement enriches the evaluative criteria, allowing for more culturally and socially attuned technology assessments.

Moreover, the commentary emphasizes methodological innovation. Integrating equity demands multidimensional models capable of capturing facets such as geographic accessibility, gender disparities, and socioeconomic status impacts on health outcomes. Conventional numeric thresholds and utility measurements, as argued, are insufficient to encapsulate these complex realities. Siriram and Harris suggest incorporating qualitative data alongside quantitative metrics, forging a more holistic understanding of a technology’s value beyond mere cost-to-benefit ratios.

Another pivotal feature of their argument concerns addressing the structural determinants that hinder equitable healthcare delivery, such as systemic poverty, infrastructural weaknesses, and historic marginalization. They argue that technology alone cannot bridge these gaps if HTA fails to account for the social milieu into which these technologies are deployed. Thus, equity-oriented assessment frameworks must evaluate not only efficacy and efficiency but also the capacity of health systems and communities to absorb and sustain the benefits.

Siriram and Harris also illuminate the ethical dimensions intertwined with adapting HTA for equity. Decision-making processes must align with principles of fairness and distributive justice, ensuring that marginalized groups are not left behind in the wave of technological advancement. This ethical imperative requires transparency about the trade-offs involved and explicit mechanisms to protect vulnerable populations from potential unintended consequences of new technologies.

In practical terms, integrating equity into HTA in LMICs necessitates building local capacity. Siriram and Harris underscore the importance of investing in training and institutional frameworks that empower local stakeholders to conduct and interpret assessments with an equity lens. This strategy reduces reliance on imported models and fosters ownership, leading to decision-making processes better aligned with national health priorities and sociocultural realities.

Policy implications arising from their commentary are profound. National governments, international donors, and global health organizations must recalibrate funding and support structures to prioritize equity-driven HTA reforms. This includes encouraging research that probes the intersection of technology, equity, and health outcomes, as well as reformulating guidelines and standards used worldwide to acknowledge diversity in health needs and contexts.

The commentary does not suggest discarding cost-effectiveness but rather repositioning it within a broader evaluative framework where economic efficiency coexists with social justice goals. This dual approach could prevent the marginalization of technologies that may be less cost-effective in narrow terms but crucial for reducing health disparities and improving population well-being within disadvantaged groups.

Siriram and Harris’s reflections are particularly timely amid the global health spotlight on pandemic preparedness, digital health expansion, and the pursuit of universal health coverage. These contexts amplify the stakes of equitable technology allocation and prompt urgent conversations about the frameworks guiding these critical decisions. The authors’ call for adaptive, equity-sensitive HTA models may well define the future trajectory of ethical global health innovation.

Their commentary ultimately serves as a clarion call to policymakers, researchers, and practitioners alike: equity is not a peripheral concern but the very foundation upon which health technologies must be assessed if the goal is health systems that serve all, especially the underserved. As South Africa and other LMICs navigate their unique health challenges, embedding equity within HTA offers a pathway towards more just, effective, and sustainable health technologies impacting millions.

In sum, the work by Siriram and Harris marks a seminal contribution to the ongoing discourse on health equity and technology assessment. By interrogating foundational assumptions and proposing practical pathways for reform, their reflective commentary invites a paradigm shift—one that could transform global health priorities and reimagine the promise of health technologies in LMICs with fairness at the center.

Subject of Research:
Adapting global health technology assessment frameworks to incorporate equity considerations, focusing on South Africa and other low- and middle-income countries (LMICs).

Article Title:
Beyond cost-effectiveness: a reflective commentary on adapting global health technology assessment for equity considerations in South Africa and other LMICs.

Article References:
Siriram, C., Harris, R. Beyond cost-effectiveness: a reflective commentary on adapting global health technology assessment for equity considerations in South Africa and other LMICs. Int J Equity Health 24, 316 (2025). https://doi.org/10.1186/s12939-025-02676-z

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12939-025-02676-z

Formulary lists are a compilation of medications that are approved for use within a particular health system or insurance policy. These lists are crucial for ensuring that patients receive appropriate and effective treatments while maintaining cost-effectiveness. However, disparities often exist between what is available in these formularies and what patients actually need. This gap can lead to delayed treatments, exacerbation of health conditions, and overall dissatisfaction among patients and healthcare providers alike.

The authors delve into the metrics of formulary access, providing a comprehensive assessment of how current practices hinder optimal patient care. By examining the barriers that patients face in accessing medications listed in formularies, the researchers highlight systemic flaws in healthcare policies that can lead to inequities in treatment access. Such barriers can include complicated prior authorization processes, high out-of-pocket costs, and insufficient communication between patients and healthcare providers.

One of the fundamentally important aspects discussed in the study is the impact of formulary accessibility on health outcomes. The researchers provide statistical evidence that indicates a proportional relationship between improved access to medications and enhanced patient outcomes. When patients can easily access the medications they need, they are more likely to adhere to treatment plans, leading to better management of chronic diseases such as diabetes, hypertension, and heart disease. This finding reinforces the notion that medication access is not merely a financial issue, but rather a pivotal factor in achieving optimal health results.

Furthermore, the paper outlines several innovative strategies for enhancing formulary accessibility. These recommendations are not just theoretical; they are grounded in successful models from various healthcare systems that have already begun to make strides in this area. For example, the introduction of streamlined formularies has shown promise in reducing confusion for both healthcare providers and patients. By simplifying the list of medications, providers can more easily prescribe appropriate treatments without fearing bureaucratic red tape or unexpected costs to patients.

In addressing the complex issue of affordability, the authors present the idea of value-based insurance design. This approach aligns patient costs with the value of the medications to their health outcomes, thus incentivizing adherence and promoting more judicious use of healthcare resources. Such models have the potential to shift the focus from merely containing costs to actively investing in medications that deliver tangible benefits for patients.

The implications of these findings extend beyond just patient care, reaching into the broader scope of public health and community wellbeing. When healthcare systems invest in improving formulary accessibility, they not only enhance individual patient experiences but also contribute to overall population health improvement. Enhanced access can lead to reduced hospital admissions, lower emergency room visits, and improved management of communicable and non-communicable diseases, thereby alleviating pressure on healthcare infrastructure.

Moreover, the authors emphasize the importance of stakeholder engagement in reforming formulary practices. Collaborative efforts involving patients, healthcare providers, policymakers, and pharmaceutical companies are essential for creating comprehensive solutions that address the multifaceted nature of formulary accessibility. The authors suggest that improving communication channels and establishing feedback mechanisms can empower patients, giving them a voice in the formulary process and keeping their needs at the forefront of healthcare discussions.

Another significant point raised in the paper is the role of technology in bridging gaps in formulary accessibility. The advent of telemedicine and electronic health records has the potential to transform how providers interact with patients and manage prescriptions. Integrating apps and online platforms that provide real-time formulary information can immediately address concerns about medication availability, allowing for quicker clinical decision-making and enhanced patient satisfaction.

While the authors acknowledge the challenges associated with achieving these reforms, they remain optimistic about the future of formulary accessibility. They argue that with concerted effort and a commitment to patient-centered care, healthcare systems can evolve to embrace models that prioritize access and affordability. This journey towards better health outcomes necessitates ongoing research and advocacy to dismantle systemic barriers that currently impede patient access to necessary medications.

The study serves as a clarion call for stakeholders in the healthcare arena to prioritize formulary accessibility as a foundational aspect of care delivery. As healthcare becomes increasingly complex, the need for streamlined and transparent processes has never been greater. The authors urge system-level changes that not only aim to enhance access but also foster a culture of collaboration and innovation in addressing the healthcare needs of diverse populations.

In conclusion, Agbafe, Kesselheim, and Barbieri contribute significant insights into the conversation surrounding formulary accessibility and clinical care. Their findings underscore the vital link between access to medications and the overall effectiveness of healthcare delivery. By investing in strategies that enhance formulary accessibility, healthcare systems can take a crucial step towards a more equitable, effective, and patient-oriented model of care that benefits individuals and communities alike.

In a healthcare landscape often defined by complexity and cost, the message is clear: improving formulary accessibility is not just a policy adjustment; it is an essential strategy for ensuring better health for all.

Subject of Research: Enhancing formulary accessibility in healthcare systems.

Article Title: Enhancing Formulary Accessibility: a Step Toward Better Care.

Article References:

Agbafe, V.C., Kesselheim, A.S. & Barbieri, J.S. Enhancing Formulary Accessibility: a Step Toward Better Care.
J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-10029-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11606-025-10029-3

Keywords: formulary accessibility, patient care, healthcare systems, medication access, health outcomes.